Michael Schlander1,2. 1. German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), & University of Heidelberg, Heidelberg, Germany. 2. Institute for Innovation & Valuation in Health Care (InnoValHC), Wiesbaden, Germany.
Abstract
There are at least two reasons why health technology assessment (HTA) agencies need to seek process-based solutions to support the legitimacy of healthcare resource allocation, ie, (i) in pluralistic societies, the existence of often conflicting and incommensurable claims (ie, the "fragmentation of value") and the lack of a broadly accepted, ethically defensible analytical framework, and (ii) the well-documented loopholes of the conventional logic of cost-effectiveness (CE) with its reductionist concept of allocative efficiency, which fails to reflect the distributive dimension of resource allocation decisions in collectively financed health schemes.
There are at least two reasons why health technology assessment (HTA) agencies need to seek process-based solutions to support the legitimacy of healthcare resource allocation, ie, (i) in pluralistic societies, the existence of often conflicting and incommensurable claims (ie, the "fragmentation of value") and the lack of a broadly accepted, ethically defensible analytical framework, and (ii) the well-documented loopholes of the conventional logic of cost-effectiveness (CE) with its reductionist concept of allocative efficiency, which fails to reflect the distributive dimension of resource allocation decisions in collectively financed health schemes.
Authors: Wija Oortwijn; Don Husereau; Julia Abelson; Edwine Barasa; Diana Dana Bayani; Vania Canuto Santos; Anthony Culyer; Karen Facey; David Grainger; Katharina Kieslich; Daniel Ollendorf; Andrés Pichon-Riviere; Lars Sandman; Valentina Strammiello; Yot Teerawattananon Journal: Int J Technol Assess Health Care Date: 2022-06-03 Impact factor: 2.406
Authors: Wija Oortwijn; Don Husereau; Julia Abelson; Edwine Barasa; Diana Dana Bayani; Vania Canuto Santos; Anthony Culyer; Karen Facey; David Grainger; Katharina Kieslich; Daniel Ollendorf; Andrés Pichon-Riviere; Lars Sandman; Valentina Strammiello; Yot Teerawattananon Journal: Value Health Date: 2022-06 Impact factor: 5.101